Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-11-25 00:00:00 ET · period of report 2025-11-24 · accession 0001867788-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-25 | 2025-11-24 | ARQT | LIN SUE-JEAN | Dir | M - OptEx | $8.31 | +25.3K | 52.0K | +95% | +$210.0K |
| D | 2025-11-25 | 2025-11-24 | ARQT | LIN SUE-JEAN | Dir | S - Sale+OE | $30.78 | -25.3K | 26.7K | -49% | -$777.9K |
| DM | 2025-11-25 | 2025-11-24 | ARQT | LIN SUE-JEAN | Dir | M - OptEx | $0.00 | -25.3K | 5,000 | -83% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-24 | M | A | 18,052 | $8.63 | 44,787 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-24 | S | D | 25,272 | $30.78 | 26,735 | D | — | — | (F3) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-11-24 | M | A | 7,220 | $7.51 | 52,007 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2025-11-24 | M | D | 18,052 | $0.00 | 9,000 | D | $8.63 · — to 2034-06-14 | 18,052 Common Stock | (F1) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. |
| 5 | Derivative | Stock Option (right to buy) | 2025-11-24 | M | D | 7,220 | $0.00 | 5,000 | D | $7.51 · — to 2033-05-31 | 7,220 Common Stock | (F2) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. |